Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Schmeiser

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Rheumatology (Oxford, England)|April 26, 2020
Older age onset of systemic sclerosis - accelerated disease progression in all disease subsetsPia Moinzadeh, Kathrin Kuhr, Elise Siegert, et al.
European Journal of Internal Medicine|May 26, 2026
Anti-Ro/SSA and rheumatoid factor antibodies are associated with more severe lung involvement in patients with systemic sclerosis: a study from the EUSTAR databaseBlaž Burja, Marouane Boubaya, Cosimo Bruni, et al.
The Journal of Rheumatology|April 3, 2019
Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ ComplicationPia Moinzadeh, Kathrin Kuhr, Elise Siegert, et al.
Arthritis Research & Therapy|November 24, 2022
Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registryNorbert Blank, Marc Schmalzing, Pia Moinzadeh, et al.
Rheumatology (Oxford, England)|January 28, 2023
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic SclerosisMichael Kreuter, Francesco Bonella, Norbert Blank, et al.
RMD Open|April 17, 2023
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseasesRebecca Hasseli, Jutta G Richter, Bimba Franziska Hoyer, et al.
Chest|August 15, 2023
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic SclerosisPia Moinzadeh, Francesco Bonella, Max Oberste, et al.
Frontiers in Medicine|March 21, 2024
The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registriesRebecca Hasseli, Frank Hanses, Melanie Stecher, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort studyGabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.
RMD Open|November 3, 2022
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohortSimon Kuster, Suzana Jordan, Muriel Elhai, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Rheumatology (Oxford, England)|April 26, 2020
Older age onset of systemic sclerosis - accelerated disease progression in all disease subsetsPia Moinzadeh, Kathrin Kuhr, Elise Siegert, et al.
European Journal of Internal Medicine|May 26, 2026
Anti-Ro/SSA and rheumatoid factor antibodies are associated with more severe lung involvement in patients with systemic sclerosis: a study from the EUSTAR databaseBlaž Burja, Marouane Boubaya, Cosimo Bruni, et al.
The Journal of Rheumatology|April 3, 2019
Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ ComplicationPia Moinzadeh, Kathrin Kuhr, Elise Siegert, et al.
Arthritis Research & Therapy|November 24, 2022
Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registryNorbert Blank, Marc Schmalzing, Pia Moinzadeh, et al.
Rheumatology (Oxford, England)|January 28, 2023
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic SclerosisMichael Kreuter, Francesco Bonella, Norbert Blank, et al.
RMD Open|April 17, 2023
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseasesRebecca Hasseli, Jutta G Richter, Bimba Franziska Hoyer, et al.
Chest|August 15, 2023
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic SclerosisPia Moinzadeh, Francesco Bonella, Max Oberste, et al.
Frontiers in Medicine|March 21, 2024
The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registriesRebecca Hasseli, Frank Hanses, Melanie Stecher, et al.
Annals of the Rheumatic Diseases|August 9, 2019
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort studyGabriele Valentini, Dörte Huscher, Antonella Riccardi, et al.
RMD Open|November 3, 2022
Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohortSimon Kuster, Suzana Jordan, Muriel Elhai, et al.
Pageof 3